SVB Wealth’s Ligand Pharmaceuticals LGND Stock Holding History

SVB Wealth’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-23	Closed	-$2.42K	–	1123
2025 Q1	$2.42K	Buy	+23	New	+$2.6K	﹤0.01%	1194

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SVB Wealth's LGND Position: Q2 2025 in Review

SVB Wealth sold out of Ligand Pharmaceuticals (LGND) in Q2 2025, closing a stake of 23 shares — an estimated $2.42K sold.

SVB Wealth first reported a position in LGND in Q1 2025 and held it in 1 quarter. The position peaked at $2.42K in Q1 2025. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

SVB Wealth reported no remaining Ligand Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 23 Ligand Pharmaceuticals shares in Q2 2025, an estimated $2.42K.
SVB Wealth first reported a position in Ligand Pharmaceuticals in Q1 2025 and held it in 1 quarter.
SVB Wealth's Ligand Pharmaceuticals position peaked at $2.42K in Q1 2025.
271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.